In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute found.
Kevan Shokat, a professor of cellular and molecular pharmacology at UC San Francisco, has won the second annual Stephenson Global Prize for research in pancreatic cancer.
